双歧杆菌三联活菌肠溶胶囊在急性白血病化疗相关性腹泻患儿中的应用效果

Application effect of Bifidobacterium Triple Viable Bacteria Enteric-Coated Capsules in children with acute leukemia chemotherapy-related diarrhea

目的探讨双歧杆菌三联活菌肠溶胶囊治疗急性白血病化疗相关性腹泻患儿的效果以指导临床用药。方法选取2017年3月至2021年3月在青岛大学附属泰安市中心医院血液病诊疗中心儿童血液病房初治急性白血病化疗相关性腹泻患儿50例作为研究对象,按照随机数字表法将其分为试验组和对照组,每组各25例。两组患儿均给予静脉补液等对症支持治疗,试验组在对症支持治疗的基础上口服双歧杆菌三联活菌肠溶胶囊,1粒/次,2~3次/d,共治疗2周。比较两组患儿的腹泻天数,治疗前、治疗2周后粪便中双歧杆菌、嗜酸乳杆菌、大肠埃希菌菌落数,血浆内毒素及D-乳酸含量、粪便钙卫蛋白水平。结果试验组患儿的腹泻时间短于对照组,差异有统计学意义(P<0.05)。试验组患儿治疗2周后粪便中的双歧杆菌、嗜酸乳杆菌菌落数多于对照组,差异有统计学意义(P<0.05);试验组患儿治疗2周后粪便中大肠埃希菌菌落数少于对照组,差异有统计学意义(P<0.05);试验组患儿治疗2周后的血浆内毒素、D-乳酸及粪便钙卫蛋白水平低于对照组,差异有统计学意义(P<0.05)。结论双歧杆菌三联活菌肠溶胶囊能缩短急性白血病患儿化疗相关性腹泻时间,调节肠道菌群平衡紊乱,改善肠道黏膜屏障功能,值得临床推广。

Objective To investigate the curative effect of Bifidobacterium Triple Viable Bacteria Enteric-Coated Capsules in the treatment of children with acute leukemia chemotherapy-related diarrhea in order to guide clinical medication.Methods Fifty children with chemotherapy-related diarrhea associated with acute leukemia who were initially treated in the Children′s Hematology Ward of the Hematology Diagnosis and Treatment Center of Tai′an Central Hospital Affiliated to Qingdao University from March 2017 to March 2021 were selected as the research subjects.According to the random number table method,they were divided into the experimental group and the control group,with 25 cases in each group.Both groups were given symptomatic and supportive treatment such as intravenous infusion,while the experimental group was added with oral administration of Bifidobacterium Triple Viable Enteric-Coated Capsules,1 capsule each time,2-3 times per day,for a total of 2 weeks of treatment.The time of diarrhea,the colony counts of Bifidobacterium,Lactobacillus acidophilus,and Escherichia coli in feces,plasma endotoxin and D-lactic acid content,and fecal calprotectin levels were compared between the two groups before treatment and after 2 weeks of treatment.Results The diarrhea time of the children in the experimental group was shorter than that in the control group,and the difference was statistically significant(P<0.05).The colony counts of Bifidobacterium and Lactobacillus acidophilus in feces 2 weeks of treatment in the experimental group were more than those of the control group,the differences were statistically significant(P<0.05).The number of Escherichia coli colonies in the feces of the children in the experimental group was less than that in the control group after 2 weeks of treatment, the difference was statistically significant (P<0.05). The children in the experimental group were treated for 2 weeks, the levels of plasma endotoxin, D-lactic acid, and fecal calprotectin were lower than those in the control group, and the differences were statistically significant (P<0.05). Conclusion Bifidobacterium Triple Viable Enteric-Coated Capsules can shorten the time of chemotherapy-related diarrhea in children with acute leukemia, regulate the balance of intestinal flora, and improve the intestinal mucosal barrier function, which is worthy of clinical promotion.